The class of small leucine-rich proteoglycans (SLRPs) is a family of homologous proteoglycans harboring relatively small (36-42 kDa) protein cores as compared to the larger cartilage and mesenchymal proteoglycans. SLRPs have been localised to most skeletal regions with specific roles designated during all phases of bone formation including periods relating to cell proliferation, organic matrix deposition, remodelling, and mineral deposition. This is mediated by key signaling pathways regulating osteogenic program, including the activity of TGF-β, BMP, Wnt or NF-κ κ κ κB, which influence both the number of available osteogenic precursors, as well as their subsequent development, differentiation and function. SLRP depletion, on the other hand, is correlated to degenerative diseases such as osteoporosis or ectopic bone formation. This review will focus on the SLRP roles in bone physiology and pathology.
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SLRP Structure and Classification
The small leucine-rich proteoglycans (SLRPs) 1 were originally defined as proteoglycans with a relatively small protein core (36-42 kDa), harboring tandem leucine-rich repeats (LRRs) and undergoing post-translational modifications including substitution with glycosaminoglycan side chains of various types (1, 2) . Their ubiquitous tissue distribution, their expression at strategic sites in embryogenesis and tissue repair, coupled with their protein conservation suggests that SLRP functions are of no small consequence. Originally, the SLRPs were grouped into three distinct classes based on nucleotide and protein sequence conservation, the organization of disulfide bonds at their N-and C-termini and their genomic organization (2, 3) . More recently, the SLRP gene family has expanded to encompass 18 genes classified into five distinct sub-families (Table I) (4, 5) additionally based on N-terminal Cys-rich clusters of the protein core and ear repeats (C-terminal repeats specific to SLRPs) (6) , chromosomal organization (4, 5) , and importantly, on functional commonality in view of the fact that some of SLRPs are not classical proteoglycans (4) . Thus, canonical class I members decorin (Dcn) and biglycan (Bgn), contain chondroitin or dermatan sulfate side chains, whereas more recently described asporin (Asp) does not (7, 8) . On the other hand, all class II members bear keratan sulfate chains or polylactosamine in their LRRs whereas class III members carry keratan sulfate (osteoglycin), chondroitin⁄ dermatan sulfate (epiphycan) or no glycosaminoglycan (opticin) chains (4, 9) . However, most non canonical class IV and V members (10) (11) (12) (13) unexpectedly lack any GAG chain, with the exception of chondroadherin which is substituted with keratan sulfate (10) . Therefore, the unique characteristics of their protein cores, as well as the presence of GAGs, together with specific post-translational modifications, notably changes in degree of GAG epimerization or sulfation, characterize this class of proteoglycans with high structural complexity.
SLRP Functional Network
Following synthesis, most of the SLRPs are secreted into the pericellular matrix where they either diffuse and bind to components of the ECM, e.g., collagens, or remain free. The localization of the SLRPs in the ECM appears to be strictly predetermined with specific SLRPs being predominantly distributed in ECM "proper" (i.e. further removed from the cell or interterritorial) whereas others are localized both to the ECM and pericellular matrix (territorial, immediately surrounding cells) (7, 14, 15) . In addition, the localization of SLRPs to specific compartments is dependent on tissue of origin (16, 17) . ECM "proper" SLRPs bind to various types of collagens thereby regulating the kinetics, assembly, and special organization of fibrils in skin, tendons, bone and cornea ( Fig. 1A) (2, (18) (19) (20) . However, ECM "proper" SLRPs besides being mainly sequestered in the ECM, can also exist as soluble molecules, e.g. when released from the ECM by proteolytic digestion of injured tissues. Both bound and soluble SLRPs interact with various growth factors, including transforming growth factor beta (TGF-β) (Fig. 1B ) (21), bone morphogenetic protein (BMP-4) (22), Wnt-I-induced secreted protein-1 (WISP-1) (23), von Willebrand factor (VWF) (24), plateletderived growth factor (PDGF) (25), tumor necrosis factor-alpha (TNF-α) (26) and insulinlike growth factor I (IGF-I) (27). This biological interaction modulates growth factor bioavailability through the formation of specific concentration gradients. On the other hand, SLRP pericellular localization allows these molecules to interact with different ligands and cell-surface receptors, thereby modulating a wide range of cell-matrix interactions (4) . Pericellular decorin binds EGFR and ErbB4 in tumor cells, leading to transient activation of the mitogen-activated protein kinase (MAPK) pathway, mobilization of intracellular Ca 2+ levels, induction of the cyclin-dependent kinase (CDK) inhibitor p21
WAF1
(28) with subsequent downregulation of the receptor (29-31). Furthermore, decorin binds directly to Met, the receptor for hepatocyte growth factor (32), which is noteworthy as signalling through Met leads to the phosphorylation of β-catenin, a known effector of the crucial Wnt signalling pathway that upregulates tumor cells motility, tissue invasion and metastasis.
Under physiological conditions, decorin signalling through IGF-IR exerts anti-apoptotic effects, favouring in this manner normal cell growth. By binding to the IGF-IR, decorin  triggers phosphorylation and downstream  activation of phosphoinositide-3 kinase, Akt⁄  protein kinase B and p21 WAF1 , inducing an antiapoptotic effect (27). Another class I SLRP, Bgn, acts as a signaling molecule important for the innate immune system. Upon tissue stress or injury, sequestered and immunologically inactive biglycan is released from the ECM through so far undefined proteolytic mechanism. Soluble biglycan interacts with the innate immunity Tolllike receptors (TLR)-2 and -4 on macrophages, taking on a role of an endogenous ligand and consequently triggering an inflammatory response (33, 34). This role could also be relevant in tumor biology as active Toll-like receptor signalling in tumor cells was shown to affect transformed cell functions (35, 36). A recent report (37) has shown that also decorin binds to TLR-2/4 thereby inducing the production of the pro-inflammatory programmed cell death 4 (PDCD4) in macrophages. Moreover, decorin prevents the translation repression of PDCD4 via induction of microRNA-21, a PDCD4 repressor. Thus, decorin can boost pro-inflammatory activity and concurrently retard tumor growth by induction of PDCD4 and microRNA-21.
Additional signalling pathways have also been identified for the class II SLRP, lumican. Fas-Fas ligand (FasL) signaling, a key cellular pathway, was found to be disrupted in Lum-/-stromal cornea keratocytes (38). Consequently, it has been proposed that that lumican could directly bind FasL thereby facilitating induction of Fas. Poor signaling through Fas-FasL in Lum-/-mice ultimately leads to attenuated apoptosis of stromal cells, impaired induction of inflammatory cytokines, impaired recruitment of inflammatory cells, and retarded corneal healing. Lumican appears to regulate fibroblast proliferation by modulating specific cell growth mediators. Thus, Lum-/-fibroblasts have decreased p21
WAF1 , a universal inhibitor of cyclin-dependent kinases and a consequent increase in cyclins A, D1, and E. Furthermore, the tumor suppressor, p53, an upstream regulator of p21 WAF1 , is downregulated in Lum-/-fibroblasts, suggesting regulation of p21
WAF1 by lumican in a p53-dependent way (38). Lumican overexpression was found to suppress tumorigenic transformation of rat fibroblast induced by v-src and v-K-ras (39) suggesting that down-regulation of lumican expression may play a role in development of some human cancers. In a recent study by Nikitovic et al. (40) , lumican was found to modulate the crucial Smad signaling pathway in bone tumor cells.
Given that SLRP production, turnover and ultimate localization are dynamic processes, variable SLRP availability at different compartments would facilitate signaling pathways regulating specific biological and pathological processes (41) . However, the exact mechanisms regulating equilibrium between "free' and bound SLRPs clearly need to be further studied. Some important questions that need to be answered would be how changes in the ECM composition shunt more bound SLRP into the free pool and to what extent is their release dependent on the degradation of the retaining ECM. Furthermore, we should also consider the activities of processed SLRP fragments vis-à-vis the parent proteins, especially relevant under pathological conditions. Indeed, significant proteolysis of SLRP protein cores occurs in both normal and arthritic tissue, with specific catabolites of biglycan and fibromodulin identified only in the cartilage from damaged joints (42) .
The collective findings summarized above clearly indicate that numerous pathways can be affected by the SLRPs. Whether the same pathways are operative in bone biology and musculoskeletal tissues is not entirely clear at this time. However, these investigations provide a fundamental platform upon which to build and deepen our understanding of SLRP function in bone (Fig. 1B) 
Key Roles of SLRPs in Bone Physiology
It is now firmly established that specific SLRPs are functionally involved in normal bone development and homeostasis. Using a combination of in situ hybridization and immunohistochemistry, class I SLRPs, biglycan and decorin, have been localized to many skeletal regions including articular and epiphyseal cartilage, vascular canals, subchondral regions and the periosteum (43) . SLRPs have specific roles during all phases of bone formation including periods relating to cell proliferation, organic matrix deposition, remodelling, and mineral deposition (44, 45) . Generation of mutant mice with targeted deletion of Bgn has shown that the biglycan-deficient mice are viable and have no profound skeletal patterning abnormalities at birth. However, with age, their long bones show decreased length, coupled with decreased mineral density and mass compared to age-matched controls (46) . Biglycan deficiency leads to structural abnormalities in collagen fibrils in bone, dermis, and tendon, and to a "subclinical" cutaneous phenotype with thinning of the dermis but without overt skin fragility (47) . Furthermore, male mice depleted of biglycan (The Bgn gene is located on the X chromosome; thus, male mice do not contain a second allele of Bgn) designated Bgn−/0, +/0 exhibit reduced bone formation compared to controls indicating that biglycan is important for the cells that control bone production (47) .
The key role of biglycan in bone development is corroborated by the observation that bone marrow ablation in biglycan-null mice leads to delayed osteogenesis (48) . Specifically, mice deficient in Bgn develop age-dependent osteopenia and have multiple metabolic defects in their bone marrow stromal cells including increased apoptosis, reduced numbers of colonyforming units and decreased collagen production (48) . Therefore, the strategy of using mice deficient in one or more SLRP has enabled identification of early molecular events causing skeletal abnormalities that are dependent on SLRP function.
In view of the fact that the BGN gene maps to the X chromosome, patients with Turner Syndrome (45 chromosomes, X0) have reduced biglycan expression and exhibit short stature, infertility and early-onset osteoporosis. In contrast, patients with supernumerary sex chromosomes (e.g., Kleinefelter syndrome) show increased biglycan expression and longer limbs (49) . Thus, bone metabolism in biglycan-deficient mice could be gender dependent. Indeed, in contrast to male mice, the bone tissue of female mice is less affected, suggesting a gender difference in biglycan skeletal function.
Biglycan can also control key signalling pathways regulating the osteogenic program, including the activity of the multifunctional cytokines TGF-β (50), BMP4 (22, 51) and Wnt (52) (Fig. 1C-E) . Consequently, biglycan can affect the number of available osteogenic precursors as well as their subsequent development, differentiation and function in bone formation.
The phenotypic analysis of the Dcn-/-;Bgn-/-double null mice reveals that the pathological bone phenotype is more severe and appears evident earlier as compared to Bgn-deficient mice. In addition to gross skeletal phenotype appearance, Bgn and Dcn double deficiency results in a striking change in collagen fibril shape and organization to an extent that is greater than the additive effect. Therefore the effects of Dcn/Bgn deficiency in bone are likely synergistic even though Dcn deficiency does not appear to affect bone phenotype by itself (47) . This could partly be explained by the suggestion that absence of biglycan and decorin prevents TGF-β from proper sequestration within the extracellular matrix. First, decorin and subsequently biglycan, asporin, and fibromodulin were found to bind TGF-β (21, 53) forming SLRP/TGF-β complexes which are either eliminated from the tissue (via the circulation or by urinary excretion), or in the presence of collagen I, are sequestered in the ECM thus downregulating TGF-β signalling (54) (55) (56) . However, the interaction of SLRPs with TGF-β could also enhance the bioactivity of TGF-β, as seen in the case of decorin during the process of bone formation during remodeling (57) or muscle formation (58) . Therefore, the direct binding of excess TGF-β to its receptors on bone marrow stromal cells could cause a "switch in fate" from growth to apoptosis and thus ultimately lead to decreased numbers of osteoprogenitor cells and subsequent reduced bone formation (50) . Furthermore, biglycan promotes osteoblast differentiation through ERK phosphorylation and signal transduction through the transcription factor Runx2 (Fig. 1C) (59) alternatively, biglycan protein core can bind to BMP2 and BMP2 activin receptor-like kinase 6 (ALK6) thereby sustaining the binding of BMP2/ALK6 (Fig. 1D) . The BMP2-Biglycan-ALK6 complex could phosphorylate Smad 1/5/8, and thus facilitate their downstream signalling relevant to osteogenesis (60) . Recently, biglycan was suggested to support Wnt signaling in vivo in a manner beneficial to bone formation (52) . In this latter study, biglycan promoted binding of Wnt3a to bone matrix by a direct interaction that involved further interface with a key Wnt co-receptor in bone LRP6 (Fig.  1E) .
Lumican is a major proteoglycan component of bone matrix. It is secreted by both differentiating and mature osteoblasts but not by proliferating pre-osteoblasts and therefore it can be used as a marker to distinguish proliferating pre-osteoblasts from the differentiating osteoblasts (61) . Keratocan expression is correlated with a more differentiated osteoblast phenotype whereas histomorphometric analysis indicates that Kera-/-mice have significantly decreased rates of bone formation and mineral apposition (62) . Male epiphycan (Dspg3)-deficient mice also have significantly shorter femurs than wild type mice at 9 months. Knee joints from Dspg3/Bgn doublenull mice display increased matrix protein expression vis-à-vis wild-type mice. This enhanced expression also includes other SLRP members such as asporin, fibromodulin and lumican demonstrating compensatory mechanisms among different SLRP family members (63) . The importance of SLRPs in bone homeostasis is further illuminated by the finding that individual members show species-specific and age-related changes that correlate with altered homeostasis of the aging skeleton (64) . Another example of the importance of SLRPs in bone biology is offered by PRELP which can downregulate osteoclastogenesis apparently by inhibiting NF-κΒ activity (65) . (46) . Subsequently it was proposed that the altered collagen phenotypes in mice deficient in one or more SLRPs demonstrate a cooperative, sequential, timely orchestrated action of the SLRPs that altogether shape the architecture and mechanical properties of the collagen matrix (66) . The development of osteoporosis among other disease states, by SLRP-deficient mice suggests that mutations in SLRPs may be part of undiagnosed predisposing genetic factors specific for the disease (66) . On the other hand, biglycan deficiency was found to protect against increased trabecular bone turnover and bone loss in response to estrogen depletion, supporting the concept that biglycan may modulate both formation and resorption ultimately influencing the bone turnover process (67) . In addition to normal bone turnover the SLRPs have been shown to contribute to ectopic ossification (68) of soft tissues. While both singly depleted biglycan and fibromodulin mice develop ectopic bone in tendon, the effect is exaggerated when the two SLRP's are deleted simultaneously, thus suggesting synergistic activities for these two SLRPs on this function (69) . Recently, in vivo osteolysis experiments showed that LPS (lipopolysaccharide)-induced osteolysis occurred more rapidly and extensively in Bgn-deficient mice compared to wild-type mice due to increased osteoclast differentiation and activity secondary to defective osteoblasts (70) . Moreover, deregulation of matrix protein expression including that of biglycan was demonstrated in hypophosphatemia (Hyp) mice with osteomalacia (71) .
Roles in Degenerative Bone Diseases
Considering that the depletion of SLRPs exacerbates degenerative diseases such as osteoporosis, osteoarthritis or ectopic bone formation, and taking into account an evermore aging population, rife with skeletal issues, one should consider novel therapies such as the use of SLRP's to ameliorate these pathological conditions.
Roles in Bone Tumor Progression
Malignant bone tumors are characterized by the presence of undifferentiated osteoprogenitors that proliferate and develop a mass of tumor tissue recognized as osteosarcoma. The expression and consequent function of SLRPs in primary bone tumors is known to differ as compared to diseasefree tissue. The absence of biglycan message observed in osteosarcoma samples and some osteosarcoma cell lines provides evidence for alterations in the extra cellular matrix which result with non-mineralized osteoid produced by the osteosarcoma cells (72) . Dissection of the sets of genes that control the behavior of Bgn-null preosteoblasts using oligonucleotide microarrays revealed that Bgn deficiency affects the genes that control inflammation, immune response, and growth of tumor cells (73) . Indeed, biglycan affects osteoblastic tumor cell behavior as it was recently suggested that osteosarcoma cells utilize Runx2 and the FGF-2-syndecan-heparan sulfate proteoglycan axis, a key effector of the osteogenic program, to regulate their migration in a manner dependent on biglycan expression (74) . Furthermore, osteosarcoma markers of poor response to therapy (Huvos I/II response grade defines tumors with little or no response to chemotherapy) are predominantly gene products involved in microenvironmental remodeling and osteoclast differentiation including Bgn (75) . On the other hand, gene chip analysis has demonstrated that biglycan had the highest expression (out of 137 genes) in giant cell tumors of bone (76) . Moreover, a series of chondrosarcomas, malignant tumors of cartilage, epidemiologically established as the second most common primary malignant neoplasm of the skeleton in adults (77) were found to have upregulated DCN transcript levels (78) whereas; a human chondrosarcoma cell line was found to express higher amounts of BGN and not to express DCN (79) .
Decorin had several-fold reduced expression in osteoblastic osteosarcoma patients compared with non-osteoblastic osteosarcoma patients that could be correlated to a poorer prognosis of the first patient group (80) . Immunohistochemistry using polyclonal and monoclonal antibodies against ECM molecules, including decorin have proved to be a useful tools for the differential characterisation of osteoid in a series of 20 osteosarcomas with different variants of osteoid formation (81) . Importantly, several studies have shown that the histological subtype of osteosarcoma is a predictive factor for response to chemotherapy (82, 83) and correlates with disease-free period (84, 85) and overall survival (86) . Moreover, decorin was found to suppress murine osteosarcoma lung metastasis, which correlated to lower adhesion and motility capabilities of the decorin-expressing osteosarcoma cells (87) . Collectively, these findings strongly correlate with the well established anti-tumor properties of decorin (88) . Interestingly, the only exception to the established oncosuppression model is the case of the highlyaggressive MG-63 human osteosarcoma cells, found to constitutively produce decorin, and furthermore, to be resistant to decorin-induced growth arrest (89) .
The role of lumican in osteosarcoma pathogenesis has previously been reviewed (90) . Indeed, the generation of LUM-deficient osteosarcoma cells suggested that LUM expression may be positively correlated with the differentiation and negatively correlated with the progression of osteosarcoma (40) . Furthermore, a novel out-in signaling circuit in human osteosarcoma cells was described: secreted lumican was found to be an endogenous inhibitor of TGF-β2 activity, resulting in downstream effector modulation including pSmad 2, integrin β1 and pFAK to regulate osteosarcoma adhesion (91) . Fibromodulin expression, on the other hand was shown to be regulated by BMP signalling pathway and thus possibly correlated to osteoblastic-origin cell transformation (92) .
Potential Therapeutic Agents for Bone Diseases
SLRPs, as regulators of signaling molecules, may hold promise for treatment and prevention of disease. The modulation of Bgn gene expression has been proposed to represent a mechanism to counteract mineralized bone loss under conditions of estrogen depletion (67) . Trans-osseous application of low-intensity ultrasound at the tendon graft-bone healing interface stimulated endogenous expression of Bgn and collagen I, thereby enhancing tendon-bone healing (93) . The above studies support utilization of biglycan therapy as a credible therapeutic venue to reduce or block degenerative bone diseases. Proof-ofprinciple for the possibility of such an application derives from a recent study showing that injections of biglycan into dystrophin-deficient mdx mice can repair numerous defects that mimic muscular dystrophy, including the improvement of muscle function (94) . In this regard it can be noted that exogenously applied recombinant biglycan could "rescue" impaired LRP6 signalling caused by a mutation in the extra-cellular domain of this Wnt receptor (54) . Thus, the specific location and function of SLRPs outside the cell lend themselves to accessibility for effective and simple therapeutic intervention.
In the case of primary bone tumors, osteosarcomas, decorin-expressing osteosarcoma cells were found to have decreased ability to generate pulmonary metastases in a mouse model, thus demonstrating that decorin has the therapeutic potential to reduce lung metastasis in osteosarcoma (87) . One important aspect in considering the role of SLRPs in tumor growth and establishment is the role of the tumor microenviroment. Indeed, many SLPRs including biglycan, decorin and fibromodulin are expressed in stroma and at least in the case of fibromodulin, appear to control its structure and integrity (95) .
Concluding Remarks
In conclusion, this review has highlighted the important roles that some SLRPs have in bone physiology and disease. These small proteoglycans are established to specifically regulate both bone osteogenesis and remodelling as well as to participate in the progression of commonly debilitating degenerative bone diseases. Further progress in discerning the specific signalling pathways in skeletal development and homeostasis is needed. Because of SLRP participation in multiple degenerative, inflammatory and neoplastic diseases, we expect that some of SLRP secreted gene products could become reliable biomarkers for bone diseases and perhaps become target of novel therapeutic interventions. Finally, we should point out that some of the pharmacological therapeutics currently-used in clinical settings, such as corticosteroid and anti-inflammatory drugs; have profound effects on SLRP synthesis and accumulation. These, in turn, could affect not only the structural composition of bone but also the myriad of bone-specific growth factors that ultimately affect bone remodelling and diseases. Lumican is proposed to bind FasL (38), modulate TGF-β signaling (40) and interact with p65 nuclear factor kappaB (NF-κB) (65) .
III

Epiphycan (EPYC) Opticin (OPTC) Osteoglycin (OGN)
The three members of this class are characterized by a relatively low number of LRRs (seven LRRs) and a genomic organization comprising seven exons. Even though most of these SLRPs have a consensus sequence for glycanation, some of them exist as glycoproteins in tissues (4, 9) .
Opticin binds growth hormone (9) .
IV
Chondroadherin (CHAD) Nyctolopin (NYC) Tukushi (TSKU)
Class IV, a non-canonical class of SLRPs, is proposed to consist of chondroadherin and nyctalopin (10, 11) and of a new member called tsukushi (12) . Nyctalopin is very interesting, being the first described glycosylphosphatidylinositol-anchored member and the second linked to the X chromosome (11) . Tsukushi shares functional properties with class I SLRPs (12) Tsukushi is a BMP inhibitor that forms a ternary complex with BMP and chordin (12) .
V
Podocan (PODN)
Podocan-like protein-1(PODN-1) Class V, a new non-canonical class of SLRPs is proposed to contain two genes, podocan located on chromosome 1 and a highly homologous podocanlike protein 1 (NCBI accession number 079101) located on chromosome 19. Although these proteins have a different C-terminal Cys rich cluster, they have 20 LRRs with homology to class I and II molecules. Moreover, Podocan binds collagen and increases p21 expression (13) . podocan binds collagen I and inhibits cell growth via induction of p21, both functional properties shared by other SLRP members (13) .
